Author:
Kamioner Didier,Fruehauf Stefan,Maloisel Fréderic,Cals Laurent,Lepretre Stéphane,Berthou Christian
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference49 articles.
1. Lyman GH: Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone. 2006, 8 (Suppl 5): S12-S18.
2. Stokes ME, Muehlenbein CE, Marciniak MD, Faries DE, Motabar S, Gillespie TW, Lipscomb J, Knopf KB, Buesching DP: Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm. 2009, 15 (8): 669-682.
3. Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004, 100 (2): 228-237. 10.1002/cncr.11882.
4. de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, Group EGW: Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010, 21 (Suppl 5): v252-v256.
5. Aapro M, Crawford J, Kamioner D: Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?. Support Care Cancer. 2010, 18 (5): 529-541. 10.1007/s00520-010-0816-y.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献